Mesenchymal Stromal Cells: Potential Option for COVID-19 Treatment

The COVID-19 pandemic has significantly impacted the way of life worldwide and continues to bring high mortality rates to at-risk groups. Patients who develop severe COVID-19 pneumonia, often complicated with ARDS, are left with limited treatment options with no targeted therapy currently available....

Full description

Bibliographic Details
Published in:Pharmaceutics
Main Authors: Dragan Primorac, Martin Čemerin, Vid Matišić, Vilim Molnar, Marko Strbad, Lenart Girandon, Lucija Zenić, Miomir Knežević, Stephen Minger, Denis Polančec
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Subjects:
COVID-19
mesenchymal stromal cells
MSCs
immunomodulation
ARDS
Online Access:https://www.mdpi.com/1999-4923/13/9/1481

Internet

https://www.mdpi.com/1999-4923/13/9/1481

Similar Items